FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896589175> ?p ?o ?g. }

• W2896589175 endingPage "e256" @default.
• W2896589175 startingPage "e256" @default.
• W2896589175 abstract "In the present study, we evaluated the appropriate schedule of S-1 administration in combination with radiotherapy for T2N0 glottic cancer by investigating the safety and efficacy. Between 2007 and 2016 23 patients diagnosed with T2N0 glottic cancer and treated with chemoradiotherapy (CRT) were enrolled in this study. Sixteen patients were treated with daily administration of S-1 (80-120 mg/day) during the course of radiotherapy between March 2007 and June 2013. Briefly, they received the drug for 4 weeks followed by 2-week drug-free intervals, or for 2 weeks followed by 1-week drug-free intervals. The remaining 7 patients were treated with an alternate-day regimen (80 mg/day) intended to reduce severe mucositis between July 2013 and December 2016. Radiotherapy was given as a once-daily fraction at 2 Gy up to a total median dose of 70 Gy (range, 66-70). The rates of survival and local control were estimated by the Kaplan-Meier method, and the Log Rank test was used to evaluate the significance of the survival and local control. The CTCAE ver. 4.0 was used to grade toxicities, and the chi-squared test was used to compare the toxicity between the daily and alternate-day administration groups. The median follow-up of the daily and alternate-day administration groups was 76 months (range: 44-104 months) and 40 months (range: 14-50 months), respectively. One patient in the alternate-day administration group experienced local recurrence and underwent total laryngectomy at eight months after the completion of CRT. A comparison between the daily administration and alternate-day administration groups at 2 years showed that the overall survival rate was 100% vs. 100%, (p = 0.68), and the local control rate was 100% vs. 86% (p = 0.13). Grade 2+ mucositis was observed in 13 patients (81%) in the daily administration group and in 3 patients (43%) in the alternate-day administration group (p=0.0656). No Grade 3 mucositis was encountered in the alternate-day administration group. Opioid pain medication to reduce symptoms was used in 9 patients (69%) in the daily administration group and in 1 patient (14%) in the alternate-day administration group (p = 0.0618). An interruption of radiotherapy due to mucosal pain was carried out in 4 patients (25%) in the daily administration group and in no patients (0%) in the alternate-day administration group (p = 0.1455). Our results suggest that an alternate-day administration regimen of S-1 for CRT might reduce mucositis without compromising the therapeutic effectiveness compared to a daily administration regimen. CRT with alternate-day administration of S-1 may therefore be a viable standard treatment option for T2N0 glottic cancer." @default.
• W2896589175 created "2018-10-26" @default.
• W2896589175 creator A5004085793 @default.
• W2896589175 creator A5018762174 @default.
• W2896589175 creator A5076433168 @default.
• W2896589175 creator A5088234785 @default.
• W2896589175 date "2018-11-01" @default.
• W2896589175 modified "2023-10-14" @default.
• W2896589175 title "Investigation of the Optimum S-1 Dosing Schedule of Concurrent Chemoradiotherapy for T2N0 Glottic Cancer: A Comparison of Alternate-Day Administration Versus Daily Administration" @default.
• W2896589175 doi "https://doi.org/10.1016/j.ijrobp.2018.07.841" @default.
• W2896589175 hasPublicationYear "2018" @default.
• W2896589175 type Work @default.
• W2896589175 sameAs 2896589175 @default.
• W2896589175 citedByCount "0" @default.
• W2896589175 crossrefType "journal-article" @default.
• W2896589175 hasAuthorship W2896589175A5004085793 @default.
• W2896589175 hasAuthorship W2896589175A5018762174 @default.
• W2896589175 hasAuthorship W2896589175A5076433168 @default.
• W2896589175 hasAuthorship W2896589175A5088234785 @default.
• W2896589175 hasBestOaLocation W28965891751 @default.
• W2896589175 hasConcept C126322002 @default.
• W2896589175 hasConcept C141071460 @default.
• W2896589175 hasConcept C2776530083 @default.
• W2896589175 hasConcept C2777288759 @default.
• W2896589175 hasConcept C2778424827 @default.
• W2896589175 hasConcept C2778496288 @default.
• W2896589175 hasConcept C2781413609 @default.
• W2896589175 hasConcept C509974204 @default.
• W2896589175 hasConcept C71924100 @default.
• W2896589175 hasConceptScore W2896589175C126322002 @default.
• W2896589175 hasConceptScore W2896589175C141071460 @default.
• W2896589175 hasConceptScore W2896589175C2776530083 @default.
• W2896589175 hasConceptScore W2896589175C2777288759 @default.
• W2896589175 hasConceptScore W2896589175C2778424827 @default.
• W2896589175 hasConceptScore W2896589175C2778496288 @default.
• W2896589175 hasConceptScore W2896589175C2781413609 @default.
• W2896589175 hasConceptScore W2896589175C509974204 @default.
• W2896589175 hasConceptScore W2896589175C71924100 @default.
• W2896589175 hasIssue "3" @default.
• W2896589175 hasLocation W28965891751 @default.
• W2896589175 hasOpenAccess W2896589175 @default.
• W2896589175 hasPrimaryLocation W28965891751 @default.
• W2896589175 hasRelatedWork W1821727971 @default.
• W2896589175 hasRelatedWork W1919481286 @default.
• W2896589175 hasRelatedWork W1978232913 @default.
• W2896589175 hasRelatedWork W2064900812 @default.
• W2896589175 hasRelatedWork W2110923848 @default.
• W2896589175 hasRelatedWork W2132010426 @default.
• W2896589175 hasRelatedWork W2233758049 @default.
• W2896589175 hasRelatedWork W2336726368 @default.
• W2896589175 hasRelatedWork W2977309342 @default.
• W2896589175 hasRelatedWork W2185375481 @default.
• W2896589175 hasVolume "102" @default.
• W2896589175 isParatext "false" @default.
• W2896589175 isRetracted "false" @default.
• W2896589175 magId "2896589175" @default.
• W2896589175 workType "article" @default.